<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Insulin therapy - type 2 diabetes | Management | Insulin therapy in type 2 diabetes | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers general information on insulin therapy for people with type 2 diabetes."/><meta data-react-helmet="true" property="og:description" content="Covers general information on insulin therapy for people with type 2 diabetes."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/insulin-therapy-in-type-2-diabetes/management/insulin-therapy-type-2-diabetes/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Insulin therapy - type 2 diabetes | Management | Insulin therapy in type 2 diabetes | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/insulin-therapy-in-type-2-diabetes/management/insulin-therapy-type-2-diabetes/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Insulin therapy in type 2 diabetes</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Insulin therapy - type 2 diabetes</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/insulin-therapy-in-type-2-diabetes/","name":"Insulin therapy in type 2 diabetes"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/insulin-therapy-in-type-2-diabetes/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Insulin therapy - type 2 diabetes"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Insulin therapy in type 2 diabetes: </span><span>Scenario: Insulin therapy - type 2 diabetes</span></h1><p class="page-header__lead"><span>Last revised in January 2021</span></p></div><p class="visually-hidden">Covers general information on insulin therapy for people with type 2 diabetes.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Insulin therapy in type 2 diabetes chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Insulin therapy - type 2 diabetes"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Insulin therapy - type 2 diabetes</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#when-to-consider-insulin-therapy">When to consider insulin therapy</a><ol aria-label="Sections within When to consider insulin therapy" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-d47">Basis for recommendation</a></li></ol></li><li><a href="index.html#self-monitoring-of-blood-glucose">Self-monitoring of blood glucose</a><ol aria-label="Sections within Self-monitoring of blood glucose" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-907">Basis for recommendation</a></li></ol></li><li><a href="index.html#available-insulin-products">Available insulin products</a><ol aria-label="Sections within Available insulin products" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-86f">Basis for recommendation</a></li></ol></li><li><a href="index.html#insulin-regimens">Insulin regimens</a><ol aria-label="Sections within Insulin regimens" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#insulin-regimen-options">Insulin regimen options</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-b10">Basis for recommendation</a></li></ol></li><li><a href="index.html#accessories-for-insulin-therapy">Accessories for insulin therapy</a><ol aria-label="Sections within Accessories for insulin therapy" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-b60">Basis for recommendation</a></li></ol></li><li><a href="index.html#injection-site-problems">Injection site problems</a><ol aria-label="Sections within Injection site problems" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-2b6">Basis for recommendation</a></li></ol></li><li><a href="index.html#persistent-poor-glucose-control">Persistent poor glucose control</a><ol aria-label="Sections within Persistent poor glucose control" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-321">Basis for recommendation</a></li></ol></li><li><a href="index.html#additional-information-advice">Additional information and advice</a><ol aria-label="Sections within Additional information and advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#storage">Storage</a></li><li class=""><a href="index.html#administration-absorption">Administration and absorption</a></li><li class=""><a href="index.html#injection-technique">Injection technique</a></li><li class=""><a href="index.html#injection-sites">Injection sites</a></li><li class=""><a href="index.html#driving">Driving</a></li><li class=""><a href="index.html#insurance">Insurance</a></li><li class=""><a href="index.html#fasting-including-ramadan">Fasting, including Ramadan</a></li><li class=""><a href="index.html#work">Work</a></li><li class=""><a href="index.html#holidays-travel">Holidays and travel</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-4bf">Basis for recommendation</a></li></ol></li><li><a href="index.html#hypoglycaemia">Hypoglycaemia</a><ol aria-label="Sections within Hypoglycaemia" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#recognizing-hypoglycaemia">Recognizing hypoglycaemia</a></li><li class=""><a href="index.html#managing-impaired-awareness-of-hypoglycaemia">Managing impaired awareness of hypoglycaemia</a></li><li class=""><a href="index.html#managing-acute-hypoglycaemia">Managing acute hypoglycaemia</a></li><li class=""><a href="index.html#managing-nocturnal-hypoglycaemia">Managing nocturnal hypoglycaemia</a></li><li class=""><a href="index.html#preventing-hypoglycaemic-episodes">Preventing hypoglycaemic episodes</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-db7">Basis for recommendation</a></li></ol></li><li><a href="index.html#other-adverse-effects-of-insulin">Other adverse effects of insulin</a><ol aria-label="Sections within Other adverse effects of insulin" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-3d0">Basis for recommendation</a></li></ol></li><li><a href="index.html#drug-interactions">Drug interactions</a><ol aria-label="Sections within Drug interactions" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-fd4">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="insulin-therapy-type-2-diabetes" class="ChapterBody-module--wrapper--2HCfk "><h2 id="insulin-therapy-type-2-diabetes" class="visually-hidden">Scenario: Insulin therapy - type 2 diabetes</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2604ed25-a79f-45ec-a407-3be1b6d78c55 --><!-- begin field 7132af68-4a9c-4065-b6bb-acd900abcadc --><p>From age 12 months onwards.</p><!-- end field 7132af68-4a9c-4065-b6bb-acd900abcadc --><!-- end item 2604ed25-a79f-45ec-a407-3be1b6d78c55 --></div><section aria-labelledby="when-to-consider-insulin-therapy" class="ChapterBody-module--wrapper--2HCfk "><h3 id="when-to-consider-insulin-therapy">When should insulin therapy be considered in a person with type 2 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f7ead284-e649-4012-b067-03e9cfa4b4cd --><!-- begin field f817f28d-83a0-437e-8e24-1d28228dab87 --><p><strong>Insulin therapy for people with type 2 diabetes should only be initiated and managed by healthcare professionals with the relevant expertise and training, including a discussion of the relative</strong><strong> benefits and risks of insulin therapy.</strong></p><ul><li><strong>In adults with type 2 diabetes:</strong><ul><li>Insulin therapy should be considered for people:<ul><li>With poor blood glucose control associated with marked symptoms, such as polyuria, polydipsia, and unintended weight loss.</li><li>With poor blood glucose control despite maximum tolerated doses of other antidiabetic drug treatment. See the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-2/index.html">Diabetes - type 2</a> for more information on oral antidiabetic drugs.</li><li>With suboptimal blood glucose control who are at high risk of complications, for example due to young age.</li><li>Where oral antidiabetic drugs are contraindicated or not tolerated. See the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-2/index.html">Diabetes - type 2</a> for more information on oral antidiabetic drugs.</li></ul></li><li>Possible barriers for initiating insulin therapy may include:<ul><li>Obesity — insulin treatment may lead to further weight gain, with little or no improvement in blood glucose control.</li><li>Physical comorbidities including reduced dexterity and vision; frailty; limited life expectancy — the potential benefits of insulin therapy may not outweigh the potential risks including risk of <a class="topic-reference internal-reference" href="index.html#hypoglycaemia">hypoglycaemia</a> and falls.</li><li>Psychological issues including anxiety about needles or painful injections; depression; cognitive impairment.</li><li>Personal preference.</li><li>Concerns about <a class="topic-reference internal-reference" href="index.html#driving">driving</a> or <a class="topic-reference internal-reference" href="index.html#holidays-travel">travel</a> on insulin therapy.</li><li>Personal preference.</li></ul></li></ul></li><li><strong>In children and young people with type 2 diabetes,</strong> the discussion on whether to start insulin therapy and ongoing education should be made by the multidisciplinary paediatric diabetes team, taking into account the age, maturity, and individual needs of the child and family/carers.</li></ul><!-- end field f817f28d-83a0-437e-8e24-1d28228dab87 --><!-- end item f7ead284-e649-4012-b067-03e9cfa4b4cd --></div><section aria-labelledby="basis-for-recommendation-d47" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-d47">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d47bfb0d-f9ea-439c-a013-8a352c57d052 --><!-- begin field 9bc6cbdd-de9a-4ed7-90a3-6a54766a300a --><p>The recommendations on initiating insulin therapy are based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Type 2 diabetes in adults: management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>] and <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>], the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Insulin treatment in children and adolescents with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>], the Royal College of Nursing (RCN) guideline <em>Starting injectable treatment in adults with type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>], the American Diabetes Association (ADA) publication <em>Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes - 2020</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">American Diabetes Association, 2020</a>], and expert opinion in a review article on barriers to insulin therapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Russell-Jones, 2018</a>].</p><h5>Insulin therapy in adults</h5><ul><li>The recommendations on when to consider initiating insulin therapy in adults are based on the NICE clinical guideline on adults [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>], the RCN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>], and the ADA publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">American Diabetes Association, 2020</a>].<ul><li>The RCN guideline notes that poor blood glucose control associated with marked symptoms often suggests pancreatic beta cell failure, and this may be associated with a good clinical response to insulin therapy. The ADA publication recommends the early introduction of insulin if there is evidence of ongoing catabolism (weight loss), symptoms of hyperglycaemia, or persistently raised HbA1c levels, for example.</li></ul></li><li>The information on possible barriers to starting insulin therapy is based on the RCN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>]. In addition, expert opinion in a review article notes that there may be 'clinical or therapeutic inertia' in intensifying diabetes treatment regimens, causing delays in insulin initiation, dose adjustment, and intensification, and an increased risk of diabetes-related complications. It highlights possible reasons for non-initiation of insulin including concerns about weight gain and hypoglycaemia adverse effects, fear of injections and self-monitoring blood glucose, concerns about impact on daily life, and comorbid mental health conditions such as anxiety and depression [<a class="bibliography-reference internal-reference" href="../../references/index.html">Russell-Jones, 2018</a>].</li></ul><h5>Insulin therapy in children</h5><ul><li>The recommendation on when to consider initiating insulin therapy in children and young people is extrapolated from the NICE clinical guideline on children and young people [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>].</li><li>The ISPAD guidelines note the need for appropriate education and discussion about insulin therapy to be based on the age, maturity, and individual needs of the child/family [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>].</li></ul><!-- end field 9bc6cbdd-de9a-4ed7-90a3-6a54766a300a --><!-- end item d47bfb0d-f9ea-439c-a013-8a352c57d052 --></div></section></section><section aria-labelledby="self-monitoring-of-blood-glucose" class="ChapterBody-module--wrapper--2HCfk "><h3 id="self-monitoring-of-blood-glucose">What do I need to know about self-monitoring of blood glucose in people with type 2 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 48402195-94d5-4b18-8d13-0d66980cbe80 --><!-- begin field bcc55d29-aa90-49c5-bd69-0542a9cfac70 --><ul><li><strong>Adults should be educated on the need for regular self-monitoring of blood glucose levels at the time of initiation of insulin therapy, by a healthcare professional with appropriate experience and expertise. </strong><br><ul><li>Educate about the need for <a class="topic-reference internal-reference" href="index.html#accessories-for-insulin-therapy">insulin accessories</a> such as a blood glucose meter, lancets, and testing strips.</li><li>Ensure a structured assessment is carried out at least annually, including:<ul><li>Self-monitoring skills, the quality and frequency of testing, and the equipment used.</li><li>That the person knows how to interpret the blood glucose results, and what action to take if they are too high or too low.</li><li>The person's individualized treatment target. See the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-2/index.html">Diabetes - type 2</a> for more information on treatment targets.</li><li>The impact of self-monitoring on the person's quality of life and the continued benefit to the person.</li></ul></li></ul></li><li><strong>For children and young people,</strong> ensure the multidisciplinary paediatric diabetes team provides advice on self-monitoring of blood glucose, treatment targets, and follow up.</li></ul><!-- end field bcc55d29-aa90-49c5-bd69-0542a9cfac70 --><!-- end item 48402195-94d5-4b18-8d13-0d66980cbe80 --></div><section aria-labelledby="basis-for-recommendation-907" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-907">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9070ef55-8461-4788-a3bc-4598c877cf74 --><!-- begin field a6471acb-56b6-49d1-bf5b-55ff05a13f91 --><p>The recommendations on self-monitoring of blood glucose are based on the National Institute for Health and Care Excellence (NICE) clinical guideline<em> </em><em>Type 2 diabetes in adults: management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>], the joint American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) consensus report <em>Management of hyperglycemia in type 2 diabetes, 2018</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>], and the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">DiMeglio, 2018</a>].</p><ul><li>The ISPAD guidelines highlight the importance of blood glucose self-monitoring to track immediate and daily levels of blood glucose control, to help determine immediate and ongoing basal and bolus requirements of insulin, to detect and manage episodes of hypoglycaemia or hyperglycaemia, and to help guide adjustments to insulin therapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">DiMeglio, 2018</a>].</li></ul><!-- end field a6471acb-56b6-49d1-bf5b-55ff05a13f91 --><!-- end item 9070ef55-8461-4788-a3bc-4598c877cf74 --></div></section></section><section aria-labelledby="available-insulin-products" class="ChapterBody-module--wrapper--2HCfk "><h3 id="available-insulin-products">What insulin products are available for people with type 2 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3c1e23ef-61ad-4ea2-a1ba-74543563f5ac --><!-- begin field 11351507-6032-42e9-9c37-c5e074bb963b --><ul><li><strong>Three types of insulin are available in the UK:</strong><ul><li>Human insulins are produced by recombinant DNA technology and have the same amino acid sequence as endogenous human insulin.</li><li>Human insulin analogues are produced in the same way as human insulins, but the insulin is modified to produce a specific desired kinetic characteristic (such as an extended duration of action or faster absorption and action).</li><li>Animal insulins are extracted and purified from animal sources, either cows (bovine) or pigs (porcine).<ul><li>Animal insulins are no longer initiated in the UK but are still used occasionally in some people who cannot (or do not wish to) change to human insulins. Their use is beyond the scope of this CKS topic.</li></ul></li></ul></li><li><strong>Insulins are broadly categorized according to their time-action profiles, with different timings of onset, durations of action, and risks of <a class="topic-reference internal-reference" href="index.html#hypoglycaemia">hypoglycaemia</a>.</strong><ul><li><strong>Short-acting insulins </strong>— these aim to work like the insulin normally produced by the body to cope with glucose absorbed from a meal or drink. They have a rapid onset of action and a short duration of action. Two types are available: <ul><li>Soluble insulins — these are generally injected 30 minutes before food and have an onset of action of 30–60 minutes, and a duration of action of up to 8 hours. Examples include Human Actrapid<sup>®</sup> and Humulin S<sup>®</sup>. </li><li>Rapid-acting insulin analogues — these have a faster onset of action than soluble insulins (within 15 minutes) and a shorter duration of action (2–5 hours); they can be injected 5–15 minutes before meals, with meals, or soon after meals. Examples include Humalog<sup>®</sup> (insulin lispro), Novorapid<sup>®</sup> (insulin aspart), Fiasp<sup>®</sup> (insulin aspart), and Apidra<sup>®</sup> (insulin glulisine). </li></ul></li><li><strong>Intermediate-acting</strong> (isophane or NPH [Neutral Protamine Hagedorn]) insulins — these are used to mimic the effect of the basal insulin that is secreted continuously throughout the day. They have an onset of action of approximately 1–2 hours, maximal effects between 4–12 hours, and a duration of action of 16–35 hours. Examples include Humulin I<sup>®</sup>, Insuman basal<sup>®</sup>, and Human Insulatard<sup>®</sup>. </li><li><strong>Long-acting insulin analogues </strong>— these also mimic basal insulin but can last for a longer period than intermediate-acting insulins. They are normally used once a day and achieve a steady-state level after 2–4 days, to produce a constant level of insulin. Examples include Lantus<sup>®</sup> (insulin glargine U100), Abasaglar<sup>®</sup> (insulin glargine), Semglee<sup>®</sup> (insulin glargine), and Levemir<sup>®</sup> (insulin detemir).</li><li><strong>Ultra-long acting insulin analogues</strong> — once-daily dosing; may be useful when timing of insulin injection is not reliable every 24 hours. Examples include Tresiba<sup>®</sup> (insulin degludec) and Toujeo<sup>®</sup> (insulin glargine U300).</li></ul></li></ul><!-- end field 11351507-6032-42e9-9c37-c5e074bb963b --><!-- end item 3c1e23ef-61ad-4ea2-a1ba-74543563f5ac --></div><section aria-labelledby="basis-for-recommendation-86f" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-86f">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 86fb1b8b-5828-4bbc-a4ef-253a00c2475d --><!-- begin field 7a6aadfa-4c90-4f47-afc6-5a856cb320b7 --><p>The information on insulin products is based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>] and the key therapeutic topic <em>Safer insulin prescribing</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>], the joint American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) consensus report <em>Management of hyperglycemia in type 2 diabetes, 2018</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>], the Royal College of Nursing (RCN) guideline <em>Starting injectable treatment in adults with type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>], the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Insulin treatment in children and adolescents with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>], the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety update <em>High strength, fixed combination and biosimilar insulin products: minimising the risk of medication error</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2015</a>], and expert opinion in the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].<br></p><ul><li>The MHRA drug safety update notes that high-strength insulin products such as Tresiba<sup>®</sup> and Toujeo<sup>®</sup> have been developed for people with large daily insulin requirements to reduce the number and volume of injections, however it is important for healthcare professionals and patients to understand the insulin strength of these different products, so that the risk of medication and dose errors is minimized [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2015</a>].</li></ul><!-- end field 7a6aadfa-4c90-4f47-afc6-5a856cb320b7 --><!-- end item 86fb1b8b-5828-4bbc-a4ef-253a00c2475d --></div></section></section><section aria-labelledby="insulin-regimens" class="ChapterBody-module--wrapper--2HCfk "><h3 id="insulin-regimens">Which insulin regimen is recommended for people with type 2 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d95dc3da-f581-4cd3-8dcd-69b3835cc8c4 --><!-- begin field 0f60e437-6ba3-44cb-95d4-0f13cefe17c6 --><p><strong>Insulin therapy for people with type 2 diabetes should only be initiated and managed by healthcare professionals with the relevant expertise and training. <strong><a class="topic-reference internal-reference" href="index.html#insulin-regimen-options">Insulin regimen options</a></strong> include:</strong></p><ul><li><strong>One, two, or three insulin injections per day regimens </strong>— these are usually injections of <a class="topic-reference internal-reference" href="index.html#available-insulin-products">short-acting insulin</a> or <a class="topic-reference internal-reference" href="index.html#available-insulin-products">rapid-acting insulin analogue</a> mixed with <a class="topic-reference internal-reference" href="index.html#available-insulin-products">intermediate-acting insulin</a> (biphasic regimen). The insulin preparations may be mixed by the person at the time of injection, or a premixed product can be used. <ul><li>Premixed analogue insulins consist of a mix of a rapid-acting insulin analogue mixed with an intermediate-acting insulin analogue. Examples include Humalog<sup>®</sup> Mix 25 and 50, and NovoMix<sup>®</sup> 30.</li><li>Premixed human insulins consist of a mix of a soluble insulin with an intermediate-acting insulin. Examples include Humulin M2<sup>®</sup>, M3<sup>®</sup>, and M5<sup>®</sup>, and Insuman<sup>®</sup> Comb 15, 20, and 50. </li></ul></li><li><strong>Multiple daily injection basal-bolus insulin regimens </strong>— the person has injections of short-acting insulin or rapid-acting insulin analogue before meals, together with one or more separate daily injections of intermediate-acting insulin or <a class="topic-reference internal-reference" href="index.html#available-insulin-products">long-acting insulin analogue</a> to cover the basal requirement. This regimen offers greater flexibility for blood glucose control.</li></ul><!-- end field 0f60e437-6ba3-44cb-95d4-0f13cefe17c6 --><!-- end item d95dc3da-f581-4cd3-8dcd-69b3835cc8c4 --></div><section aria-labelledby="insulin-regimen-options" class="ChapterBody-module--wrapper--2HCfk "><h4 id="insulin-regimen-options">Insulin regimen options</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2fe912a6-8765-4abc-9899-e35ec130ae46 --><!-- begin field b65579f2-f6d7-4e96-9a32-d73058e5a767 --><p><strong>The choice of insulin therapy regimen should be individualized, and will vary depending on the person's age, duration of diabetes, lifestyle, treatment targets, risk of <strong><a class="topic-reference internal-reference" href="index.html#hypoglycaemia">hypoglycaemia</a></strong> and other <strong><a class="topic-reference internal-reference" href="index.html#other-adverse-effects-of-insulin">adverse effects</a></strong>, and patient preference.</strong></p><ul><li><strong>When starting insulin therapy in adults with type 2 diabetes:</strong><ul><li><a class="topic-reference internal-reference" href="index.html#available-insulin-products">Neutral Protamine Hagedorn</a> (NPH) insulin (injected once or twice daily according to need) should be offered first line.</li><li>NPH plus a <a class="topic-reference internal-reference" href="index.html#available-insulin-products">short-acting insulin</a> should be considered (particularly if the person’s HbA1c is 75 mmol/mol [9.0%] or higher), to be administered either separately or as a <a class="topic-reference internal-reference" href="index.html#insulin-regimens">pre-mixed</a> (biphasic) human insulin preparation.</li><li><a class="topic-reference internal-reference" href="index.html#available-insulin-products">Insulin detemir</a> or <a class="topic-reference internal-reference" href="index.html#available-insulin-products">insulin glargine</a> should be considered as an alternative to NPH insulin if:<ul><li>The person needs assistance from a carer or healthcare professional to inject insulin, and the use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily, <em>or </em></li><li>The person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes, <em>or</em></li><li>The person would otherwise need twice-daily NPH insulin injections in combination with oral antidiabetic drugs.</li></ul></li><li>Pre-mixed insulin preparations that include short-acting insulin analogues (rather than those that include short-acting human insulin preparations) should be considered if:<ul><li>A person prefers injecting insulin immediately before a meal, <em>or</em></li><li><a class="topic-reference internal-reference" href="index.html#hypoglycaemia">Hypoglycaemia</a> is a problem, <em>or </em></li><li>Blood glucose levels rise markedly after meals. </li></ul></li></ul></li><li><strong>Consider switching from NPH insulin to </strong><strong>insulin detemir or insulin glargine in adults who:</strong><ul><li>Do not reach their target HbA1c because of significant hypoglycaemia,<em> or</em></li><li>Experience significant hypoglycaemia on NPH insulin irrespective of the level of HbA1c reached, <em>or</em></li><li>Cannot use the device needed to inject NPH insulin, but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made, <em>or</em></li><li>Need help from a carer or healthcare professional to administer insulin injections, and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.</li></ul></li><li><strong>Adults on a basal insulin regimen (NPH insulin, insulin detemir, or insulin glargine) </strong>should be monitored for the need for short-acting insulin before meals (or a pre-mixed insulin preparation). </li><li><strong>Adults on pre-mixed insulin</strong> should be monitored for the need for a further injection of short-acting insulin before meals, or for a change to a basal-bolus regimen with NPH insulin, insulin detemir, or insulin glargine if blood glucose control remains inadequate.</li></ul><p>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>]</p><!-- end field b65579f2-f6d7-4e96-9a32-d73058e5a767 --><!-- end item 2fe912a6-8765-4abc-9899-e35ec130ae46 --></div></section><section aria-labelledby="basis-for-recommendation-b10" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-b10">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b10cf4c3-ea89-4f2c-aabf-6843fa1be2f9 --><!-- begin field 6182cd59-f8af-4881-9849-7b0990136faa --><p>The information on insulin regimens is based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Type 2 diabetes in adults: management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>] and the key therapeutic topic <em>Safer insulin prescribing</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>], the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Insulin treatment in children and adolescents with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>], and the Royal College of Nursing (RCN) guideline <em>Starting injectable treatment in adults with type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>].</p><ul><li>The ISPAD clinical practice consensus guidelines emphasize the importance of an individualized insulin therapy regimen, which optimizes blood glucose control and reduces the short- and long-term risks from diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>].</li></ul><!-- end field 6182cd59-f8af-4881-9849-7b0990136faa --><!-- end item b10cf4c3-ea89-4f2c-aabf-6843fa1be2f9 --></div></section></section><section aria-labelledby="accessories-for-insulin-therapy" class="ChapterBody-module--wrapper--2HCfk "><h3 id="accessories-for-insulin-therapy">What insulin accessories are needed?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 23c1f148-aa03-46d2-80a5-43de310ea4a1 --><!-- begin field eb86c3e8-bf90-4e72-8a57-689443a68f63 --><p><strong>In addition to the correct <a class="topic-reference internal-reference" href="index.html#available-insulin-products">insulin preparation</a>, people on insulin therapy will also need:</strong></p><ul><li><strong>An insulin delivery device </strong>— a variety of insulin injection devices are available, such as standard insulin U100 syringes, preloaded disposable pens, and reusable injection pens, depending on:<ul><li>The age of the person.</li><li>Dexterity (for example ease of inserting and changing cartridges). </li><li>Visual impairment (for example problems reading the dialled dose).</li><li>Personal preference.</li><li>Note: advise the person not to change their insulin delivery device without first discussing with their diabetes specialist.</li></ul></li><li><strong>Needles </strong>— sterile disposable needles are designed to fit pen injectors and are available in different lengths (from 4 mm to 12.7 mm).<ul><li>People having <a class="topic-reference internal-reference" href="index.html#injection-site-problems">injection site problems</a> should be offered needles of different lengths.</li><li>Children and young people should be provided with needles that are of appropriate length for their body fat.</li></ul></li><li><strong>A blood glucose meter, test strips, and lancets </strong>— for <a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">self-monitoring</a> blood glucose levels. <ul><li>Blood glucose monitoring meters are not prescribable on the NHS, however some brands can be obtained free of charge from the local diabetes team or the manufacturer; they can also be purchased online or from pharmacies. The choice of blood glucose meter will depend on personal preference, cost, and/or local diabetes team guidelines.</li><li>Testing strips (single-use) are prescribable on the NHS. A wide variety are available, and they are designed for use with specific proprietary blood glucose monitoring meters.</li><li>Lancets (single-use) are prescribable on the NHS. They are available in various lengths and gauges and are designed to fit into proprietary finger-pricking devices (which are usually packaged with the blood glucose meter).</li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/testing/test-strips-and-monitors" data-hyperlink-id="60c61981-cb23-4087-abdd-acbb01118f30">Test strips and monitors</a> may be helpful.</li></ul></li><li><strong>Urine ketone testing strips</strong><ul><li>Ketostix<sup>®</sup> and Mission<sup>®</sup> ketones are available on the NHS.</li></ul></li><li><strong>A blood ketone meter, test strips, and lancets</strong><ul><li>Blood ketone meters are not prescribable on the NHS, however some brands can be obtained free of charge from the local diabetes team or the manufacturer; they can also be purchased online or from pharmacies.</li><li>The following single-use testing strips are available on the NHS: <ul><li>FreeStyle Optium<sup>®</sup> beta-ketone (for the FreeStyle Optium<sup>®</sup> and Freestyle Optimum Neo<sup>®</sup> blood ketone meters).</li><li>GlucoMen<sup>®</sup> LX Ketone (for the GlucoMen<sup>®</sup> LX Plus blood ketone meter).</li></ul></li><li>Single-use lancets are also available on the NHS.</li></ul></li><li><strong>Glucose and/or glucagon kit</strong><ul><li>Glucose 40% oral gels (such as GlucoGel<sup>®</sup>) are available on prescription (and can also be purchased over-the-counter) for the <a class="topic-reference internal-reference" href="index.html#managing-acute-hypoglycaemia">management of acute hypoglycaemia</a> in people who are able to swallow safely.</li><li>Glucagon 1 mg injection (GlucaGen<sup>®</sup> Hypokit) is available on prescription for the treatment of severe hypoglycaemia.</li></ul></li><li><strong>Accessories for sharps disposal </strong>— used syringes, insulin pen devices (such as pre-filled pens), needles, and lancets are all classified as clinical waste. They must be safely stored and disposed of to prevent sharps-related injuries. The following items are available on the NHS:<ul><li>Needle-clipping (chopping) device — BD Safe Clip<sup>®</sup> is designed to clip the needle off the insulin pen after use (but is not for use with lancets).</li><li>Sharps container — Sharpsafe<sup>®</sup> and Sharpsguard<sup>®</sup> are available.</li></ul></li><li><strong>Insulin Passport or insulin safety card</strong><ul><li>The Insulin Passport is a patient-held record that shows the person's current insulin preparation(s) and is available from each insulin manufacturer.</li><li>The NHS England patient information leaflet <a href="https://www.england.nhs.uk/improvement-hub/wp-content/uploads/sites/44/2017/11/Safe-use-of-insulin-and-you-patient-info-booklet.pdf" data-hyperlink-id="167cc393-8219-4f24-8a23-acb501203743">The safe use of insulin and you</a> may be helpful.</li><li>The Diabetes UK patient resources <a href="https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/treating-your-diabetes/insulin" data-hyperlink-id="f921828f-8ccd-437e-8795-acbb010d854f">Insulin and diabetes</a> and <a href="https://www.diabetes.org.uk/guide-to-diabetes/your-child-and-diabetes/insulin-and-your-child" data-hyperlink-id="0c8fa776-9079-4b30-9ff3-acbb0112c683">Injecting insulin and children</a> may be helpful.</li></ul></li><li><strong>Identification jewellery or card </strong>— advise the person to always wear or carry some form of diabetes identification, such as a:<ul><li>MedicAlert<sup>®</sup> bracelet, necklace, or watch (available from <a href="http://www.medicalert.org.uk/" data-hyperlink-id="a38fa5f2-eb5d-4714-ab9c-a93100c1faba">www.medicalert.org.uk</a>).</li><li>Diabetes identity card or wristband (available from <a href="https://www.diabetes.org.uk/" data-hyperlink-id="77e582d5-998c-420a-9c7f-aca0010ea22e">www.diabetes.org.uk</a>).</li></ul></li></ul><!-- end field eb86c3e8-bf90-4e72-8a57-689443a68f63 --><!-- end item 23c1f148-aa03-46d2-80a5-43de310ea4a1 --></div><section aria-labelledby="basis-for-recommendation-b60" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-b60">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b602eaf6-f668-4a0e-aa8c-54ab77b8d124 --><!-- begin field 53250715-1187-49a3-ac7d-6e4b1485d460 --><p>The information on accessories for insulin therapy is largely based on the National Institute for Health and Care Excellence (NICE) key therapeutic topic <em>Safer insulin prescribing</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>], the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Insulin treatment in children and adolescents with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>] and <em>Exercise in children and adolescents with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Adolfsson, 2018</a>], the Royal College of Nursing (RCN) guideline <em>Starting injectable treatment in adults with type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>], the Medicines and Healthcare products Regulatory Agency (MHRA) device safety information <em>Managing diabetes: patients should not change their insulin delivery device without checking with their healthcare specialist</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2016</a>], and expert opinion in a review article on insulin delivery [<a class="bibliography-reference internal-reference" href="../../references/index.html">Frid, 2016</a>] and in the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><ul><li>The recommendation not to change insulin delivery device before the person discusses with their diabetes specialist is based on the MHRA device safety information, which notes that this is important to avoid the risk of hyperglycaemia, hypoglycaemia, or diabetic ketoacidosis (DKA) [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2016</a>].</li><li>The information on sharps disposal is based on consensus opinion in a review article, which notes that safe disposal of used sharps is essential to reduce the risk of sharps-related injuries and blood-borne infections [<a class="bibliography-reference internal-reference" href="../../references/index.html">Frid, 2016</a>].</li><li>The information on insulin passports and safety information is based on the NICE key therapeutic topic [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>] and the RCN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>].</li><li>The recommendation on wearing or carrying diabetes identification is based on the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Adolfsson, 2018</a>]. It is also pragmatic, based on what CKS considers to be safe clinical practice.</li></ul><!-- end field 53250715-1187-49a3-ac7d-6e4b1485d460 --><!-- end item b602eaf6-f668-4a0e-aa8c-54ab77b8d124 --></div></section></section><section aria-labelledby="injection-site-problems" class="ChapterBody-module--wrapper--2HCfk "><h3 id="injection-site-problems">How should I manage insulin injection site problems?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b32bc570-c85d-4933-a302-4746100dd55d --><!-- begin field 5f3d5f30-7b78-4d99-96fd-8a08e0f7d43c --><p><strong>Advise all people on insulin therapy and family/carers to check injection sites prior to injection.</strong></p><ul><li><strong>Offer a review of injection sites:</strong><ul><li>For children and young people, at each clinical review.</li><li>For adults, at least annually and if new problems with blood glucose control arise.</li></ul></li><li><strong>Offer advice on the management of injection site problems:</strong><ul><li><strong>Painful injections</strong><ul><li>Review the person's <a class="topic-reference internal-reference" href="index.html#injection-technique">injection technique</a>.</li><li>Consider changing the size of the needles — a shorter needle may be less painful.</li><li>Ensure that the person uses a new needle for every injection.</li><li>Ensure that insulin is not used straight from the refrigerator — cold insulin can make injection painful.</li><li>Advise the person to numb the area (for example by rubbing with a piece of ice) for 15–20 seconds before injecting.</li></ul></li><li><strong>Bleeding and bruising</strong><ul><li>Reassure the person that bleeding may occasionally occur when the needle is withdrawn.</li><li>Advise them to gently apply pressure to the site for 5–10 seconds to stop the bleeding.</li><li>Review the injection technique — bruising and bleeding can occur if the insulin is accidentally injected intramuscularly, or after tight squeezing of the skin.</li><li>Consider changing the size of the needle — a shorter needle may reduce inadvertent intramuscular injection.</li></ul></li><li><strong>Redness, swelling, and itching</strong><ul><li>Reassure the person that local reactions usually resolve after a few days (sometimes several weeks).</li><li>Consider switching to an <a class="topic-reference internal-reference" href="index.html#available-insulin-products">insulin analogue</a> if local reactions with human insulin are problematic and persist for longer than 2–4 weeks.</li><li>Exclude other causes for symptoms, such as a reaction to soap or cosmetics, poor injection technique, or reaction to the preservatives in the insulin preparations (which may require a change of insulin preparation). Information on each product's excipients (including preservatives) can be found in the Summary of Product Characteristics available at <a href="https://www.medicines.org.uk/emc" data-hyperlink-id="6e0fed59-1dec-4c42-9a4d-acb50151747b">www.medicines.org.uk</a>.</li></ul></li><li><strong>Lipodystrophies (lipohypertrophy, <strong>cutaneous amyloidosis, and </strong>lipoatrophy)</strong><ul><li>Lipohypertrophy (common) and cutaneous amyloidosis (rare) present as subcutaneous lumps at an injection site, which may interfere with insulin absorption and blood glucose control, and may persist for months. Lipohypertrophy typically regresses after stopping injection into the lesions, whereas amyloidosis does not. If cutaneous amyloidosis is suspected, arrange a dermatology referral to confirm the diagnosis.</li><li>Advise that these conditions can be minimized by alternating between the left and right side on a weekly basis, and rotating <a class="topic-reference internal-reference" href="index.html#injection-sites">injection sites</a> within the same body area. Advise the person not to inject insulin into affected areas, and to wait until the area has become soft before reusing it. The person should be aware that injection into a different unaffected site may cause hypoglycaemia, and to seek specialist advice before using a different site, as a change in insulin regimen may be needed.</li><li>Lipoatrophy (localized loss of fat tissue) may present as skin indenting and cratering and can rarely occur with use of human insulin and insulin analogues.</li></ul></li><li><strong>Insulin leakage</strong><ul><li>Advise the person to leave the needle in the skin for 5–10 seconds (or longer for large doses), to ensure that the entire dose is injected. They should <em>not</em> inject a second insulin dose to compensate for the leaked insulin.</li><li>Review the person's injection technique if leakage occurs often and consider the need for needles of different lengths.</li></ul></li></ul></li></ul><!-- end field 5f3d5f30-7b78-4d99-96fd-8a08e0f7d43c --><!-- end item b32bc570-c85d-4933-a302-4746100dd55d --></div><section aria-labelledby="basis-for-recommendation-2b6" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-2b6">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2b6b360a-b7f0-43a5-9240-09edd8bdf625 --><!-- begin field 8ccf8b9d-381c-4645-bfd6-1cd4ccd50e62 --><p>The recommendations on injection site problems are based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Type 1 diabetes in adults: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020c</a>] and <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>], the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Insulin treatment in children and adolescents with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>], the Royal College of Nursing (RCN) guideline <em>Starting injectable treatment in adults with type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>], the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety update <em>Insulins (all types): risk of cutaneous amyloidosis at injection site</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2020</a>], and expert opinion in review articles on diabetic reviews [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>] and on insulin delivery [<a class="bibliography-reference internal-reference" href="../../references/index.html">Frid, 2016</a>].</p><ul><li>The recommendation to check injection sites if there are problems with blood glucose control is based on the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>].</li><li>The information about lipodystrophies is based on the RCN publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>] and the MHRA drug safety update [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2020</a>]. The recommendation that suspected cutaneous amyloidosis should be referred to a dermatologist is based on consensus opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Frid, 2016</a>].</li></ul><!-- end field 8ccf8b9d-381c-4645-bfd6-1cd4ccd50e62 --><!-- end item 2b6b360a-b7f0-43a5-9240-09edd8bdf625 --></div></section></section><section aria-labelledby="persistent-poor-glucose-control" class="ChapterBody-module--wrapper--2HCfk "><h3 id="persistent-poor-glucose-control">How should I manage persistent poor blood glucose control in a person with type 2 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3d3942b9-1f9c-4240-b862-6d32124d971e --><!-- begin field bf55e4a9-c497-4ee0-937a-590569650a38 --><p><strong>If a person on insulin therapy has poor blood glucose control, such as hyperglycaemia (</strong><strong>HbA1c more than 48 mmol/mol or </strong><strong>plasma glucose more than 11.1 mmol/L), or hypoglycaemia (plasma glucose less than 3.5 mmol/L) at no consistent times:</strong></p><ul><li><strong>Consider the following possible causes before making changes to a previously optimized insulin regimen:</strong><ul><li>Non-adherence to insulin treatment (common cause).<ul><li>Suspect non-adherence in people who present with a hyperglycaemic emergency, such as diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS), especially if this is a recurrent problem. See the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-2/index.html">Diabetes - type 2</a> for more information on the clinical presentation and emergency management of suspected hyperglycaemic emergencies.</li><li>Encourage children and young people to attend appointments with the paediatric diabetes team regularly, to optimize blood glucose control and monitoring.</li></ul></li><li>Injection technique — inappropriate insulin <a class="topic-reference internal-reference" href="index.html#injection-technique">injection technique</a>, problems with insulin administration, and/or faulty devices can lead to erratic insulin absorption. </li><li>Injection sites — advise that <a class="topic-reference internal-reference" href="index.html#injection-sites">injection sites</a> should be rotated to ensure consistent absorption of insulin. </li><li>Blood glucose self-monitoring skills — problems with <a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">self-monitoring</a> may lead to inappropriate dose titration of insulin. </li><li>Knowledge and self-management skills — ensure the person knows how to manage their diabetes during periods of intercurrent illness, and that they are aware of possible causes and management of hyperglycaemia and <a class="topic-reference internal-reference" href="index.html#hypoglycaemia">hypoglycaemia</a>.<ul><li>Advise that increased blood glucose self-monitoring is needed during periods of intercurrent illness, and that insulin doses may need to be adjusted.</li><li>Advise that insulin must <em>not</em> be stopped during periods of intercurrent illness.</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-2/index.html">Diabetes - type 2</a> for more information on managing intercurrent illness and 'sick-day rules'.</li></ul></li><li>Lifestyle issues — diet, exercise, and alcohol intake can affect blood glucose control. </li><li>Psychosocial issues — anxiety, depression, eating disorders, behavioural and relationship problems, and lack of psychosocial support can affect a person's ability to self-manage diabetes.<ul><li>See the CKS topics on <a class="topic-reference external-reference" href="../../../generalized-anxiety-disorder/index.html">Generalized anxiety disorder</a>, <a class="topic-reference external-reference" href="../../../depression/index.html">Depression</a>, <a class="topic-reference external-reference" href="../../../depression-in-children/index.html">Depression in children</a>, <a class="topic-reference external-reference" href="../../../eating-disorders/index.html">Eating disorders</a>, and <a class="topic-reference external-reference" href="../../../conduct-disorders-in-children-young-people/index.html">Conduct disorders in children and young people</a> for more information.</li></ul></li><li>Other conditions — such as chronic kidney disease can lead to erratic blood glucose control; diabetic gastroparesis, coeliac disease, or Addison's disease can precipitate hypoglycaemic episodes. See the CKS topics on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/index.html">Chronic kidney disease</a>, <a class="topic-reference external-reference" href="../../../diabetes-type-2/index.html">Diabetes - type 2</a>, <a class="topic-reference external-reference" href="../../../../coeliac-disease.html">Coeliac disease</a>, and <a class="topic-reference external-reference" href="../../../addisons-disease/index.html">Addison's disease</a> for more information.</li></ul></li><li><strong>If insulin titration and adjustment is required, ensure this is done by a healthcare professional with the relevant expertise and training.</strong></li></ul><!-- end field bf55e4a9-c497-4ee0-937a-590569650a38 --><!-- end item 3d3942b9-1f9c-4240-b862-6d32124d971e --></div><section aria-labelledby="basis-for-recommendation-321" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-321">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 321c5f24-0347-4c72-9bc8-ddfff543704b --><!-- begin field c3644156-8b42-41fc-abe6-bf62b74fe363 --><p>The recommendations on poor blood glucose control are based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Type 1 diabetes in adults: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020c</a>], <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>], and the key therapeutic topic <em>Safer insulin prescribing</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>]; the joint American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) consensus report <em>Management of hyperglycemia in type 2 diabetes, 2018</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>]; the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Diabetic ketoacidosis and the hyperglycemic hyperosmolar state</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Wolfsdorf, 2018</a>] and <em>Assessment and management of hypoglycemia in children and adolescents with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Abraham 2018</a>]; the Royal College of Nursing (RCN) guideline <em>Starting injectable treatment in adults with type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>]; and expert opinion in review articles on 'sick-day rules' [<a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>] and on hyperglycaemic emergencies [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>].</p><ul><li>The ISPAD clinical practice consensus guidelines note that accidental or deliberate insulin omission is the cause of most cases of recurrent diabetic ketoacidosis (DKA), and underlying psychosocial issues may contribute, such as a desire to lose weight in young people or adults with an eating disorder, associated anxiety or depression, or emotional issues [<a class="bibliography-reference internal-reference" href="../../references/index.html">Wolfsdorf, 2018</a>]. Similarly, expert opinion in a review article notes that insulin omission is more often seen in people with eating disorders, people with psychological distress, and fear of hypoglycaemia or weight gain on insulin [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>].</li><li>The joint ADA/EASD consensus report notes the need for frequent blood glucose monitoring and dose titration for optimal efficacy of insulin therapy, and the fact that adverse effects and the need for frequent injections can be barriers to insulin use [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>].</li><li>The recommendations on blood glucose monitoring and insulin use during periods of intercurrent illness are based on the RCN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>] and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>]. Expert opinion in an additional review article stresses the importance of patient education in managing episodes of intercurrent illness, so that inappropriate reductions or omissions of insulin doses are avoided, which increase the risk of hyperglycaemic emergencies such as DKA or hyperglycaemic hyperosmolar state (HHS) [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>]. This recommendation is supported by the NICE key therapeutic topic [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>].</li><li>The information on lifestyle issues that can affect blood glucose control is based on the RCN guideline, which notes regular portions of long-acting carbohydrates can help stabilize blood glucose levels, and alcohol can increase the risk of delayed hypoglycaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>].</li><li>The information on other medical conditions that can affect blood glucose control and potentially increase the risk of hypoglycaemia is based on the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Abraham 2018</a>].</li></ul><!-- end field c3644156-8b42-41fc-abe6-bf62b74fe363 --><!-- end item 321c5f24-0347-4c72-9bc8-ddfff543704b --></div></section></section><section aria-labelledby="additional-information-advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="additional-information-advice">What additional information and advice should I give people with type 2 diabetes?</h3><section aria-labelledby="storage" class="ChapterBody-module--wrapper--2HCfk "><h4 id="storage">Advice on insulin storage</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 302e3a52-cedb-43d2-8f5b-5b8923cd6a86 --><!-- begin field 030a2234-24b8-4c67-8ff6-a4e0960988b1 --><p><strong>Advise the person to check the manufacturer's patient information leaflet for insulin storage information.</strong></p><ul><li>Insulin that is not currently being used should be stored in a refrigerator at 2–8°C.<ul><li>The person should keep at least one spare insulin vial or cartridge of each type of prescribed insulin.</li></ul></li><li>Insulin must not become frozen, and it should be discarded if this occurs.<ul><li>Vials or pens should not be stored in, or too near to, the freezer section or cooling element of the refrigerator.</li></ul></li><li>Once in use, insulin can generally be stored at room temperature for 28 days (some insulins may be stable for shorter or longer timescales).<ul><li>Insulin must be protected from sunlight and excessive heat (for example, it should not be placed near a cooker, on top of electrical equipment, or left in a car during hot weather).</li></ul></li></ul><!-- end field 030a2234-24b8-4c67-8ff6-a4e0960988b1 --><!-- end item 302e3a52-cedb-43d2-8f5b-5b8923cd6a86 --></div></section><section aria-labelledby="administration-absorption" class="ChapterBody-module--wrapper--2HCfk "><h4 id="administration-absorption">Advice on the administration and absorption of insulin</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d20ada3f-c4cd-4de3-867a-8c5316a88bf5 --><!-- begin field 0a02665a-22c7-45b2-8e81-ec6309075f99 --><p><strong>Advise the person and family/carers that:</strong></p><ul><li>Insulin preparations are usually given by subcutaneous injection, as insulin is destroyed by gastric acid and is not absorbed across the gut mucosa.</li><li>There is considerable day-to-day variation in insulin absorption, particularly in children.<ul><li>The rate of absorption can vary by as much as 20–40% from one day to the next in any person. This is due to local tissue reactions, changes in insulin sensitivity, blood flow, depth of injection, and/or the amount of insulin injected. Other factors that affect insulin absorption include:<ul><li>Fat mass — absorption is slower if there is a large amount of subcutaneous fat. </li><li>Age — absorption is faster in young children due to less subcutaneous fat.</li><li>Ambient and body temperature — higher temperatures lead to faster absorption.</li><li><a class="topic-reference internal-reference" href="index.html#injection-sites">Injection site</a> — the rate of insulin absorption varies depending on which part of the body is used. This may affect blood glucose control. </li><li>Exercise — this causes increased blood flow at the injection site resulting in faster absorption (for example thighs of runners). </li><li>Inadvertent intramuscular injection — due to factors such as poor <a class="topic-reference internal-reference" href="index.html#injection-technique">injection technique</a> or the use of an inappropriate needle length; absorption is faster compared with subcutaneous injection.</li><li>Larger dose — absorption is slower if a large insulin dose is injected.</li></ul></li></ul></li></ul><!-- end field 0a02665a-22c7-45b2-8e81-ec6309075f99 --><!-- end item d20ada3f-c4cd-4de3-867a-8c5316a88bf5 --></div></section><section aria-labelledby="injection-technique" class="ChapterBody-module--wrapper--2HCfk "><h4 id="injection-technique">Advice on injection technique</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 23b89eb8-7341-44dc-bbd4-6cd32f75e839 --><!-- begin field 5cd42e3a-e7f7-46fb-b930-57e03f0b0e41 --><ul><li><strong>Advise the person to:</strong><ul><li>Leave insulin at room temperature for at least 30 minutes before injecting; a longer period may be required for some insulins. Advise the person to check the manufacturer's patient information.<ul><li>Cold insulin (straight from the fridge) can make injection painful, and the insulin may take longer to absorb.</li></ul></li><li>Check the expiry date before injecting.<ul><li>Any expired insulin should be discarded (it can be returned to the pharmacy for disposal).</li></ul></li><li>Inspect the insulin product before injecting.<ul><li>Soluble insulins and long-acting insulin analogues should be clear and colourless and must not be used if they appear cloudy or discoloured.</li></ul></li><li>Use the specific product according to the manufacturer's patient information, including:<ul><li>How to prepare the insulin before use — insulin suspension products should be inverted or rotated (not shaken) at least 20 times to mix the insulin. However, soluble insulins and long-acting insulin analogues do not need to be mixed.</li><li>How to prime the pen — an air shot (sometimes referred to as 'priming the pen') should be done before each injection. This ensures that the plunger is connecting and that any air is expelled from the pen.</li><li>Never to withdraw insulin from insulin pen devices or pen refills and then administer it using a syringe and needle.</li></ul></li><li>Use a new needle for each injection.<ul><li>This reduces the risk of blood-borne infection. In addition, reused needles are less sharp and may cause more painful injections.</li></ul></li><li>Choose an appropriate <a class="topic-reference internal-reference" href="index.html#injection-sites">injection site</a>, ensuring that the site and hands are clean. <ul><li>Advise not to use alcohol wipes unless there are concerns about skin hygiene, as their use can make the injection more painful and harden the skin. Infection at injection sites is rare.</li><li>A 'two-finger pinch technique' to lift a skinfold to ensure subcutaneous (rather than intramuscular) injection may be used, particularly in young children and thin adults.</li><li>Do not inject through clothing, as this will prevent skin inspection of the injection site beforehand and make lifting a skinfold and checking for bleeding afterwards difficult.</li><li>For people injecting more than 50 units (0.5 mL of U100 insulin), many experts recommend splitting the injection into separate areas to facilitate absorption.</li></ul></li><li>Inject insulin with the needle at a 90° angle to the skin. The needle should be inserted quickly and all the way in, to ensure injection at a consistent depth.<ul><li>People using long needles (longer than 8 mm) might have to inject at an angle less than 90° to avoid intramuscular injection, however pen needles longer than 4 mm and syringe needles longer than 6 mm are not routinely recommended, as inadvertent intramuscular injection may result in variable blood glucose control and increased risk of hypoglycaemia.</li><li>The needle should be left in the skin for 5–10 seconds (or longer for large doses), to ensure the entire dose is injected and to avoid leakage of the dose.</li></ul></li><li>Apply gentle pressure over the injection site for several seconds after withdrawing the needle.<ul><li>The area should not be rubbed as this may increase the rate of insulin absorption.</li></ul></li></ul></li></ul><!-- end field 5cd42e3a-e7f7-46fb-b930-57e03f0b0e41 --><!-- end item 23b89eb8-7341-44dc-bbd4-6cd32f75e839 --></div></section><section aria-labelledby="injection-sites" class="ChapterBody-module--wrapper--2HCfk "><h4 id="injection-sites">Advice on injection sites</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5e3dbecd-01c6-42c5-83b7-9a86e71a133e --><!-- begin field 7924a658-740d-4454-b278-9622e246ef46 --><p><strong>Advise the person and family/carers:</strong></p><ul><li>To choose a body area that has plenty of subcutaneous fat, ensuring that the site and hands are clean. The main injection sites are:<ul><li>Abdomen — fastest absorption rate compared with other sites; may be less affected by muscle activity or exercise.</li><li>Anterolateral thigh — absorption rate slower than abdomen, may be preferred site for <a class="topic-reference internal-reference" href="index.html#available-insulin-products">longer-acting</a> insulins.</li><li>Lateral upper quadrant of buttocks — absorption rate slowest compared with abdomen and thigh. This site may be useful in small children.</li><li>Upper arm (not usually recommended) — absorption rate medium to fast.</li></ul></li><li>The skin should be 'pinched up' to avoid intramuscular injection, if needed.<ul><li>This is recommended especially for slim people, for injection sites that have little subcutaneous fat, and when using long needles. </li><li>This may not be necessary when using a very short needle (for example 4 mm length), or if the buttocks are used, due to the abundance of subcutaneous fat.</li></ul></li><li>To check injection sites regularly for <a class="topic-reference internal-reference" href="index.html#injection-site-problems">injection site problems</a>, and rotate sites to prevent skin problems such as lipohypertrophy.<ul><li>The person should alternate between the left and right side of the body on a weekly basis, and injection sites should be rotated within the same area. Each injection should be at least one finger's breadth away from the site of the previous injection.</li><li>Rotation grids (available from manufacturers of insulin syringes and needles) may be helpful for some people who have problems rotating injection sites.</li><li>The person should never inject into sites of lipodystrophy, inflammation, oedema, ulceration, or infection.</li></ul></li></ul><!-- end field 7924a658-740d-4454-b278-9622e246ef46 --><!-- end item 5e3dbecd-01c6-42c5-83b7-9a86e71a133e --></div></section><section aria-labelledby="driving" class="ChapterBody-module--wrapper--2HCfk "><h4 id="driving">Advice on driving</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e6a42815-fcb0-4e25-b834-88734db6dffa --><!-- begin field d20d2e62-6913-4bf5-9d5b-232d023be4f5 --><p><strong>Advise people with diabetes that it is the responsibility of the driving licence holder or applicant to notify the Driver and Vehicle Licensing Agency (DVLA) of their medical condition.</strong></p><ul><li><strong>Remind drivers of the need to be particularly careful to avoid <a class="topic-reference internal-reference" href="index.html#hypoglycaemia">hypoglycaemia</a>. </strong>They should:<ul><li>Have a supply of a <a class="topic-reference internal-reference" href="index.html#managing-acute-hypoglycaemia">fast-acting carbohydrate</a> in the vehicle and avoid driving if their meal is delayed.</li><li>Be aware of how to manage an acute episode of hypoglycaemia, including:<ul><li>Stop the car in a safe place, switch off the engine, and move from the driver's seat.</li><li>Immediately consume a fast-acting carbohydrate and recheck blood glucose levels frequently until symptoms improve or normal blood glucose is restored. See the section on <a class="topic-reference internal-reference" href="index.html#managing-acute-hypoglycaemia">Managing acute hypoglycaemia</a> for more detailed information.</li><li>Wait until 45 minutes after the blood glucose has returned to normal before continuing the journey.</li></ul></li><li>Take regular meals, snacks, and rest periods on long journeys, and always avoid alcohol.</li><li>Carry <a class="topic-reference internal-reference" href="index.html#accessories-for-insulin-therapy">diabetes identification</a> in case of injury in a road traffic collision.</li><li>Take particular care during changes of insulin regimens, changes of lifestyle, exercise, and travel.</li></ul></li><li><strong>Group 1 entitlement (to drive a car or motorcycle)</strong><br><ul><li>The person must satisfy the following criteria:<br><ul><li>Has adequate <a class="topic-reference internal-reference" href="index.html#managing-impaired-awareness-of-hypoglycaemia">awareness of hypoglycaemia</a>, such that they are 'capable of bringing their vehicle to a safe controlled stop'.</li><li>Has not had more than one episode of <a class="topic-reference internal-reference" href="index.html#recognizing-hypoglycaemia">severe hypoglycaemia</a> requiring the assistance of another person in the preceding 12 months, and the most recent episode occurred more than 3 months ago.</li><li>Performs appropriate blood glucose monitoring, defined as no more than 2 hours before the start of the first journey and every 2 hours after driving has started.</li><li>Is not regarded as a likely risk to the public while driving.</li><li>Can meet the visual standards for acuity and visual fields.</li><li>Is under regular review.</li></ul></li><li>Note: more frequent blood glucose self-monitoring may be required if there is a greater risk of hypoglycaemia, for example after physical activity or altered meal routine.</li><li>If the medical standards are met, a 1-, 2-, or 3-year licence will be issued.</li></ul></li><li><strong>Group 2 entitlement (to drive a bus or lorry)</strong><ul><li>The person must satisfy the following criteria:<ul><li>Has full <a class="topic-reference internal-reference" href="index.html#managing-impaired-awareness-of-hypoglycaemia">awareness of hypoglycaemia</a>. </li><li>Has not had any episode of <a class="topic-reference internal-reference" href="index.html#recognizing-hypoglycaemia">severe hypoglycaemia</a> requiring the assistance of another person in the preceding 12 months.</li><li>Performs regular blood glucose monitoring at least twice daily (including on days when not driving), and at times relevant to driving (no more than 2 hours before the start of the first journey and every 2 hours after driving has started). A maximum of 2 hours should pass between the pre-driving blood glucose test and the first blood glucose check performed after driving has started.</li><li>Uses a blood glucose meter with sufficient memory to store 3 months of blood glucose readings.</li><li>Can demonstrate an understanding of the risks of hypoglycaemia.</li><li>Has no disqualifying complications of diabetes that would mean a license was refused or revoked, such as visual field defect.</li></ul></li><li>Note: more frequent blood glucose self-monitoring may be required if there is a greater risk of hypoglycaemia, for example after physical activity or altered meal routine. A diabetes review is needed at least every 3 years by the person's usual doctor who provides diabetes care, including review of the last 3 months of blood glucose readings. In addition, an annual examination is needed by an independent consultant specialist in diabetes, if the examination by their usual doctor is satisfactory.</li><li>If the medical standards are met, a 1-year licence will be issued.</li></ul></li><li>The DVLA patient leaflets <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/834451/inf294-a-guide-to-insulin-treated-diabetes-and-driving.pdf" data-hyperlink-id="ca0b71eb-c79a-4cee-a88a-acb500d99d2e">A guide to insulin treated diabetes and driving</a> and <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/863517/ins186_a_guide_for_drivers_with_insulin_treated_diabetes.pdf" data-hyperlink-id="be4c2057-d6a3-42fc-a98d-acb500d99d2e">A guide for drivers with insulin treated diabetes who wish to apply for group 2 entitlement (bus and lorry)</a> may be helpful.</li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/life-with-diabetes/driving" data-hyperlink-id="4fab3f50-4eee-4756-b88e-acbb010e8b87">Driving and diabetes</a> may be helpful.</li></ul><!-- end field d20d2e62-6913-4bf5-9d5b-232d023be4f5 --><!-- end item e6a42815-fcb0-4e25-b834-88734db6dffa --></div></section><section aria-labelledby="insurance" class="ChapterBody-module--wrapper--2HCfk "><h4 id="insurance">Advice on insurance</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 913e77f3-c68b-4aff-a13d-1fa7768e16c3 --><!-- begin field fb6d8543-47b7-4f2d-bfff-47a348fe9e3b --><ul><li><strong>Inform the person using insulin therapy that:</strong><ul><li>For car insurance, they must notify their insurance company (immediately and on renewal) that they are on insulin therapy.</li><li>For insurance or assurance for loans and life cover, they must declare their diabetes and any treatment they are taking, including insulin. <ul><li>If they had not been diagnosed with diabetes at the time they took out an insurance policy, they do not need to inform their insurance company. Their premiums will not change, even if they need to start insulin.</li></ul></li><li>For travel insurance, they should check that the policy covers type 2 diabetes, as policies may exclude pre-existing medical conditions.<ul><li>If travelling within the European Union (EU), they should also apply for a Global Health Insurance Card (GHIC) to obtain free or reduced-cost healthcare treatment. This is not a replacement for appropriate travel insurance. See the gov.uk information page <a href="https://www.gov.uk/global-health-insurance-card" data-hyperlink-id="b1e007e3-0dee-4967-b7d6-acbb011d409b">Apply for a UK Global Health Insurance Card (GHIC)</a> for more information.</li></ul></li></ul></li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/life-with-diabetes/insurance" data-hyperlink-id="8fe3d6a1-8ddd-4712-95d8-acbb010f0a30">Insurance and diabetes</a> may be helpful.</li></ul><!-- end field fb6d8543-47b7-4f2d-bfff-47a348fe9e3b --><!-- end item 913e77f3-c68b-4aff-a13d-1fa7768e16c3 --></div></section><section aria-labelledby="fasting-including-ramadan" class="ChapterBody-module--wrapper--2HCfk "><h4 id="fasting-including-ramadan">Advice on fasting, including Ramadan</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 32c00f00-fd24-477a-a369-a1eec4b521b1 --><!-- begin field f132f068-50f8-4d3f-af98-b98bcb01667b --><p><strong>Advise people with type 2 diabetes that generally fasting is not recommended, especially if the person has a history of poor blood glucose control, comorbidities, and/or diabetic complications. Fasting for prolonged periods (such as Ramadan) can lead to episodes of <a class="topic-reference internal-reference" href="index.html#persistent-poor-glucose-control">hyperglycaemia</a>, ketoacidosis, <a class="topic-reference internal-reference" href="index.html#persistent-poor-glucose-control">hypoglycaemia</a>, and dehydration. </strong><strong>If a person is planning a period of fasting:</strong></p><ul><li><strong>Advise on the need for pre-fasting education before the start of the fast, including the need to:</strong><ul><li>Optimize <a class="topic-reference internal-reference" href="index.html#persistent-poor-glucose-control">blood glucose control</a>, blood pressure, and lipids. See the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-2/index.html">Diabetes - type 2</a> for more information.</li><li>Make adjustments to the type, dose, or timing of insulin regimen during the fasting period. Seek specialist advice or arrange referral to the specialist diabetes team if there is any uncertainty on how to adjust insulin therapy.</li><li><a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">Monitor blood glucose</a> levels frequently during fasting, and how to interpret and act on results. This includes awareness of 'sick-day rules', and <a class="topic-reference internal-reference" href="index.html#recognizing-hypoglycaemia">recognition</a> and acute <a class="topic-reference internal-reference" href="index.html#managing-acute-hypoglycaemia">treatment</a> of hypoglycaemia. See the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-2/index.html">Diabetes - type 2</a> for more information on 'sick-day rules'.<ul><li>Advise to break the fast immediately if there is <a class="topic-reference internal-reference" href="index.html#recognizing-hypoglycaemia">symptomatic hypoglycaemia</a> and/or the blood glucose level is less than 3.5 mmol/L.</li><li>Advise to avoid fasting if they are unwell.</li><li>Advise to avoid strenuous exercise or activity, particularly during the hours before the sunset meal, as this can increase the risk of hypoglycaemia. Encourage the person to maintain their usual physical activity (especially during non-fasting periods).</li></ul></li></ul></li><li><strong>Advise the person on dietary and nutritional adjustments needed during the fasting period:</strong><ul><li>To break the fast, a snack of short-acting carbohydrates such as milk, dates, or juice may be taken.</li><li>Encourage longer-acting carbohydrates and fruits, vegetables, lean protein, lentils, and yoghurt in the pre-dawn and sunset meals. Limit intake of saturated fats, sweets, and fried foods, and avoid sweetened drinks.</li><li>Eat the pre-dawn meal as late as possible before the start of the daily fast.</li><li>Drink water and other non-sweetened drinks at regular intervals during non-fasting hours.</li></ul></li><li><strong>The Diabetes UK patient resources <a href="https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/ramadan" data-hyperlink-id="6d70ee57-9762-4d60-920e-acbb0142fab5">Ramadan and diabetes</a> and <a href="https://www.diabetes.org.uk/guide-to-diabetes/enjoy-food/eating-with-diabetes/fasting" data-hyperlink-id="472eda05-b462-4d0f-bc5c-acbb0142fab5">Fasting and diabetes</a> may be helpful.</strong></li></ul><!-- end field f132f068-50f8-4d3f-af98-b98bcb01667b --><!-- end item 32c00f00-fd24-477a-a369-a1eec4b521b1 --></div></section><section aria-labelledby="work" class="ChapterBody-module--wrapper--2HCfk "><h4 id="work">Advice on work</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 12241141-f687-4a3e-bbe4-c3764deff465 --><!-- begin field b78a94ea-6585-4a3a-acfc-7611d92a7f52 --><ul><li>Advise people on insulin therapy that some jobs involving safety-critical work will need an individual medical assessment by the employer to determine if the person is suitable for the role, however it is unlawful for an employer to operate a blanket ban on recruitment of people with diabetes.<ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/life-with-diabetes/employment" data-hyperlink-id="f4a4d31a-35d1-4bc1-b683-acbc00b6e5c0">Work and diabetes</a> may be helpful.</li><li>Note: the UK Armed Forces are exempt from Equality Act regulations.</li></ul></li><li>Advise people that jobs involving shift work may result in an increased risk of poor <a class="topic-reference internal-reference" href="index.html#persistent-poor-glucose-control">blood glucose control</a>.<ul><li>If a person has to work shifts, ensure that they know how to adjust their insulin treatment. Arrange referral or liaise with the diabetes specialist team if there is any uncertainty on how to do this.</li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/enjoy-food/eating-with-diabetes/your-lifestyle-diabetes-and-food-" data-hyperlink-id="c2264ea5-94ec-4a13-b336-acbb01440f20">Your lifestyle, diabetes and food</a> may be helpful.</li></ul></li></ul><!-- end field b78a94ea-6585-4a3a-acfc-7611d92a7f52 --><!-- end item 12241141-f687-4a3e-bbe4-c3764deff465 --></div></section><section aria-labelledby="holidays-travel" class="ChapterBody-module--wrapper--2HCfk "><h4 id="holidays-travel">Advice on holidays and travel</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 31068e38-04ad-4b84-866a-ac5ea5db816f --><!-- begin field 1628b273-56c1-4672-8ecd-8db936d06d7f --><ul><li><strong>Offer general advice on travelling, </strong>such as:<ul><li>Carry some form of <a class="topic-reference internal-reference" href="index.html#accessories-for-insulin-therapy">diabetes identification</a> at all times.</li><li>Carry some form of <a class="topic-reference internal-reference" href="index.html#managing-acute-hypoglycaemia">fast-acting carbohydrate</a> to treat possible episodes of hypoglycaemia, and pack <a class="topic-reference internal-reference" href="index.html#managing-acute-hypoglycaemia">longer-acting carbohydrates</a> such as snack bars or biscuits in case of delayed meals.</li><li>Avoid excessive caffeine and alcohol intake, as these can affect blood glucose control, including <a class="topic-reference internal-reference" href="index.html#managing-impaired-awareness-of-hypoglycaemia">hypoglycaemia awareness</a>.</li><li>Obtain appropriate <a class="topic-reference internal-reference" href="index.html#insurance">travel insurance</a>.</li><li>Take necessary precautions if <a class="topic-reference internal-reference" href="index.html#driving">driving</a>.</li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/life-with-diabetes/travel" data-hyperlink-id="f0f943c0-6e43-4bf7-b457-acbb01169a4d">Travel and diabetes</a> may be helpful.</li></ul></li><li><strong>Offer advice on insulin management,</strong> such as:<ul><li>Carry appropriate quantities of insulin and <a class="topic-reference internal-reference" href="index.html#accessories-for-insulin-therapy">accessories</a> in their hand luggage (and a spare set on the person, in case their luggage is lost or stolen).</li><li>Carry supporting documentation from a qualified medical professional explaining the person's need to carry syringes, injection devices, insulin, blood glucose testing equipment, and sharps disposal equipment in their hand luggage, for customs and security measures at airports.</li><li>Manage their insulin regimen, including adapting the regimen if the time zone change is more than 4 hours.<ul><li>If the person is taking a long haul flight or will cross different time zones, seek specialist advice, or arrange referral to the local diabetes team.</li></ul></li></ul></li></ul><!-- end field 1628b273-56c1-4672-8ecd-8db936d06d7f --><!-- end item 31068e38-04ad-4b84-866a-ac5ea5db816f --></div></section><section aria-labelledby="basis-for-recommendation-4bf" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-4bf">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4bfd68dc-c8f8-4005-84aa-a0bf4d2ed684 --><!-- begin field 304f0534-eea8-4579-9751-acab00de491e --><p>The recommendations on additional information are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Type 2 diabetes in adults: management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>] and the key therapeutic topic <em>Safer insulin prescribing</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>]; the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Assessment and management of hypoglycemia in children and adults with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Abraham 2018</a>], <em>Exercise in children and adolescents with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Adolfsson, 2018</a>], <em>Insulin treatment in children and adolescents with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>], and <em>Fasting during Ramadan by young people with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Deeb, 2020</a>]; the Driver and Vehicle Licensing Agency (DVLA) publication <em>Assessing fitness to drive - a guide for medical professionals</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">DVLA, 2020</a>]; the Royal College of Nursing (RCN) guideline <em>Starting injectable treatment in adults with type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>]; the NHS Improvement patient safety alert <em>Risk of severe harm and death due to withdrawing insulin from pen devices</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NHS Improvement, 2016</a>]; and expert opinion in review articles on diabetic reviews [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>], on insulin delivery [<a class="bibliography-reference internal-reference" href="../../references/index.html">Frid, 2016</a>], on the management of diabetes during Ramadan [<a class="bibliography-reference internal-reference" href="../../references/index.html">Karamat, 2010</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Ibrahim, 2020</a>], and on the management of diabetes during shift work [<a class="bibliography-reference internal-reference" href="../../references/index.html">Young, 2013</a>].</p><h5>Advice on insulin storage</h5><ul><li>These recommendations are based on the ISPAD clinical practice consensus guidelines, which highlight the importance of storing spare insulin to ensure supply [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>]. They are supported by expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Frid, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</li></ul><h5>Advice on insulin administration and absorption</h5><ul><li>The information on factors that affect insulin absorption is based on the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Adolfsson, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>].</li></ul><h5>Advice on injection technique</h5><ul><li>These recommendations are largely based on the NICE clinical guideline on adults [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>], the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>], the RCN guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>], an NHS Improvement patient safety alert [<a class="bibliography-reference internal-reference" href="../../references/index.html">NHS Improvement, 2016</a>], and expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Frid, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].<ul><li>The recommendation to never withdraw insulin from pen devices or pen refills is based on an NHS Improvement patient safety alert, which warns this practice may not take account of differing dose strengths in pen devices and may lead to insulin overdose and potentially life-threatening hypoglycaemia if an incorrect volume is extracted inadvertently.</li><li>The ISPAD clinical practice consensus guidelines note that incorrect angle, length of needle, or depth of injection may cause intramuscular and painful injections.</li><li>The information that pen needles longer than 4 mm and syringe needles longer than 6 mm are not generally recommended is based on consensus opinion in a review article, which notes that these needle lengths should be used first line as they are safe, effective, and less painful than longer lengths. In addition, it notes the risks of inadvertent intramuscular injection with longer needle lengths [<a class="bibliography-reference internal-reference" href="../../references/index.html">Frid, 2016</a>].</li></ul></li></ul><h5>Advice on injection sites</h5><ul><li>The information on the absorption characteristics of different body sites is based on the ISPAD clinical practice consensus guidelines, which notes that injection into the arm may be difficult if there is little subcutaneous fat, with an increased risk of intramuscular injection and unsightly bruising [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>].</li><li>The recommendation to rotate injection sites regularly is based on the NICE clinical guideline on adults [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>] and the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>]. This approach is supported by consensus opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Frid, 2016</a>].</li></ul><h5>Advice on driving</h5><ul><li>The information on measures to take to avoid and manage an acute episode of hypoglycaemia is based on the ISPAD clinical practice consensus guidelines on hypoglycaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">Abraham 2018</a>] and on exercise [<a class="bibliography-reference internal-reference" href="../../references/index.html">Adolfsson, 2018</a>], the RCN guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>], and patient information from Diabetes UK.</li><li>The information on the medical standards for group 1 and group 2 entitlement is based on the DVLA publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">DVLA, 2020</a>]. The NICE key therapeutic topic highlights the importance of education about the DVLA driving regulations when using insulin therapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>].</li></ul><h5>Advice on insurance</h5><ul><li>These recommendations are based on the RCN guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>] and patient information on the gov.uk website.</li></ul><h5>Advice on fasting, including Ramadan</h5><ul><li>These recommendations are largely based on the ISPAD clinical practice consensus guidelines, which have been extrapolated from recommendations for children and young people with type 1 diabetes on insulin therapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Deeb, 2020</a>].<ul><li>Optimizing blood glucose control before fasting can help to ensure safe fasting. Hypoglycaemia unawareness needs to be excluded pre-fasting and monitored for during fasting.</li><li>Adjustments in the insulin regimen, such as reduction of the total daily dose of insulin, may be needed following specialist advice.</li><li>There is a need to monitor blood glucose levels frequently during fasting periods to minimize the risk of hypoglycaemia and detect periods of hyperglycaemia.</li><li>Dietary changes are needed to reduce the risk of acute complications of fasting, excessive weight gain, and adverse changes in lipid profile. Low-glycaemic index carbohydrates and lean protein at the pre-dawn meal can enhance satiety during the day.</li></ul></li><li>These recommendations are supported by the RCN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>] and expert opinion in review articles, which highlight the risks of fasting, and which note the importance of structured education and pre-Ramadan counselling [<a class="bibliography-reference internal-reference" href="../../references/index.html">Karamat, 2010</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Ibrahim, 2020</a>].</li></ul><h5>Advice on work</h5><ul><li>The information on medical suitability for employment is based on the RCN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>].</li><li>The information on shift work is extrapolated from expert opinion in a review article on management of type 1 diabetes and shift work, which notes that shift work may lead to differing activity levels, changes to meal times and sleep patterns, and snacking on high-fat foods outside normal working hours [<a class="bibliography-reference internal-reference" href="../../references/index.html">Young, 2013</a>].</li></ul><h5>Advice on holidays and travel</h5><ul><li>The recommendations on travel are largely based on the RCN guideline, which notes that insulin stored in hold baggage will be exposed to very low temperatures which will degrade insulin, and there is a possibility that luggage will be lost en-route [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>]. In addition, they are pragmatic, based on what CKS considers to be good clinical practice.</li></ul><!-- end field 304f0534-eea8-4579-9751-acab00de491e --><!-- end item 4bfd68dc-c8f8-4005-84aa-a0bf4d2ed684 --></div></section></section><section aria-labelledby="hypoglycaemia" class="ChapterBody-module--wrapper--2HCfk "><h3 id="hypoglycaemia">How should I manage hypoglycaemia?</h3><section aria-labelledby="recognizing-hypoglycaemia" class="ChapterBody-module--wrapper--2HCfk "><h4 id="recognizing-hypoglycaemia">Recognizing hypoglycaemia</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0eb4d0da-0468-4f94-9b3d-3c6784ce46ac --><!-- begin field 3006f98e-81ee-486a-b941-93dd3075c1d1 --><p><strong>Hypoglycaemia (a blood glucose level less than 3.5 mmol/L) is an inevitable adverse effect of insulin therapy.</strong> <strong>Advise that the absolute blood glucose level at which signs and symptoms begin to occur can vary between people.</strong></p><ul><li>Ensure that the person and family/carers are aware of the early warning signs of hypoglycaemia, the importance of immediate <a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">blood glucose measurement</a> if suspected, and <a class="topic-reference internal-reference" href="index.html#managing-acute-hypoglycaemia">emergency treatment</a> of an acute episode. Hypoglycaemia may present as:<ul><li>Mild — hunger, anxiety or irritability, palpitations, tremor, sweating, or tingling lips.</li></ul><ul><li>Moderate — headache, drowsiness, difficulty concentrating, impaired vision, confusion, irritability, agitation, behavioural changes (particularly in children). Impaired cognitive function occurs when blood glucose levels fall below 3.0 mmol/L.</li><li>Severe — involves severe cognitive impairment such as convulsions, loss of consciousness, and coma. The person is unable to self-manage the hypoglycaemic episode and requires help from another person to achieve normal blood glucose levels.</li></ul></li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/complications/hypos" data-hyperlink-id="d2d41f97-ebaf-43df-bc0f-acbb01100c00">What is a hypo?</a> may be useful.<br> </li></ul><!-- end field 3006f98e-81ee-486a-b941-93dd3075c1d1 --><!-- end item 0eb4d0da-0468-4f94-9b3d-3c6784ce46ac --></div></section><section aria-labelledby="managing-impaired-awareness-of-hypoglycaemia" class="ChapterBody-module--wrapper--2HCfk "><h4 id="managing-impaired-awareness-of-hypoglycaemia">Managing a person with impaired awareness of hypoglycaemia</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item bf7a8bd3-aaad-4f8e-abc5-257d4054fb2a --><!-- begin field f237009a-e931-4f2e-82b1-d64c583dd066 --><p><strong>Impaired awareness of hypoglycaemia describes the loss of ability to recognise the usual <strong><a class="topic-reference internal-reference" href="index.html#recognizing-hypoglycaemia">symptoms</a></strong> of hypoglycaemia, or the absence or blunting of symptoms. Obtain a collateral history from family/carers about the person's awareness of hypoglycaemia, where possible.</strong></p><ul><li><strong>At annual review:</strong><ul><li>Explain that impaired awareness of the symptoms of hypoglycaemia is associated with a significantly increased risk of <a class="topic-reference internal-reference" href="index.html#recognizing-hypoglycaemia">severe hypoglycaemia</a>, which can be life-threatening.<ul><li>The Driver and Vehicle Licensing Agency (DVLA) defines impaired awareness of hypoglycaemia for group 1 drivers as 'an inability to detect the onset of hypoglycaemia because of total absence of warning symptoms'.</li></ul></li><li>Ensure the person and family/carers have appropriate skills and knowledge to use insulin therapy correctly. Offer additional education focusing on avoiding and treating hypoglycaemia if the person continues to have impaired awareness of hypoglycaemia.</li><li>If the person's target blood glucose levels are lower than recommended, reinforce the recommended treatment targets. <ul><li>Avoid relaxing individualized blood glucose targets as a treatment for impaired awareness of hypoglycaemia. See the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-2/index.html">Diabetes - type 2</a> for more information on recommended treatment targets.</li></ul></li><li>Review insulin regimens and doses and prioritize strategies to avoid hypoglycaemia.<ul><li>If the person continues to have impaired awareness of hypoglycaemia and/or recurrent severe hypoglycaemia, liaise with or arrange referral to the diabetes specialist team, the urgency depending on clinical judgement.</li></ul></li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/complications/hypos/hypo-unawareness" data-hyperlink-id="62a37120-da1a-4177-97da-acbb0110abb2">Hypo unawareness</a> may be useful.</li></ul></li></ul><!-- end field f237009a-e931-4f2e-82b1-d64c583dd066 --><!-- end item bf7a8bd3-aaad-4f8e-abc5-257d4054fb2a --></div></section><section aria-labelledby="managing-acute-hypoglycaemia" class="ChapterBody-module--wrapper--2HCfk "><h4 id="managing-acute-hypoglycaemia">Managing an acute episode of hypoglycaemia</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 96adff53-1a74-480b-866b-4025c67e5461 --><!-- begin field faebde78-e079-47ab-a4da-cf63c78aebcf --><p><strong>Advise on the acute management of hypoglycaemia:</strong></p><ul><li><strong>If the person is able to swallow: </strong><ul><li>Children and young people should be given approximately 0.3 g/kg of a fast-acting carbohydrate.</li><li>Adults should promptly consume 10–20 g of a fast-acting carbohydrate, preferably in liquid form.</li><li>Examples include:<ul><li>5 glucose tablets; 6 dextrose tablets; 200 mL (small carton) of fresh fruit juice (not sugar-free or reduced-sugar); 3–4 heaped teaspoonfuls of sugar added to a cup of water; 4 large jelly babies or 7 large jelly beans; 2 tubes of glucose 40% gel (such as Glucogel<sup>®</sup>, Dextrogel<sup>®</sup> or Rapilose gel<sup>®</sup>).</li><li>Note: advise to avoid chocolates and biscuits as they have a lower sugar content, and their high fat content may delay stomach emptying.</li></ul></li><li>Advise to recheck blood glucose levels after 10–15 minutes. <ul><li>Hypoglycaemia should be reversed in about 10 minutes.</li><li>Improvements in clinical <a class="topic-reference internal-reference" href="index.html#recognizing-hypoglycaemia">signs and symptoms</a> may lag behind improvement in blood glucose level. </li></ul></li><li>If there is no response or an inadequate response, repeat oral intake as above, and re-test blood glucose levels after another 15 minutes.</li><li>When symptoms improve or normal blood glucose is restored, advise on the need for longer-acting carbohydrate to maintain blood glucose levels and prevent recurrence of hypoglycaemia. <ul><li>If the next meal is due, it should contain carbohydrate such as bread, potatoes, or pasta.</li><li>If the next meal is not due soon, the person should consume a carbohydrate-containing snack such as a sandwich, two plain biscuits, or a banana.</li></ul></li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/complications/hypos/having-a-hypo" data-hyperlink-id="6041fea3-7401-4f58-824e-acbb01105386">Having a hypo</a> may be useful.</li></ul></li><li><strong>If the</strong><strong> person is unconscious and unable to swallow (<strong><a class="topic-reference internal-reference" href="index.html#recognizing-hypoglycaemia">severe hypoglycaemia</a></strong>):</strong><ul><li>Intramuscular (IM) glucagon should be administered immediately. <ul><li>For children younger than 8 years of age (or body weight less than 25 kg), 500 micrograms of glucagon should be given. </li><li>For all other people, 1 mg of glucagon should be given. </li></ul></li><li>Emergency 999 transfer to hospital should be arranged if: <ul><li>IM glucagon is not available. </li><li>The family/carers are not trained to administer glucagon.</li><li>Alcohol is the cause of, or has contributed to, the development of hypoglycaemia, as intravenous (IV) glucose is required. </li></ul></li><li>If the person does not respond to glucagon treatment within 10 minutes, emergency 999 transfer to hospital should be arranged for treatment with IV glucose.</li><li>If the person responds to glucagon treatment within 10 minutes and is sufficiently alert and able to swallow safely, advise them to eat some oral carbohydrate (to replace the body's supply and to prevent relapse of hypoglycaemia). <ul><li>Vomiting is common in the recovery phase, and recurrent hypoglycaemia may recur, therefore the person should be closely monitored with regular blood glucose level checks.</li><li>If hypoglycaemia recurs, the person may require additional oral carbohydrate or emergency 999 hospital admission for treatment with IV glucose if symptoms are severe.</li></ul></li></ul></li></ul><!-- end field faebde78-e079-47ab-a4da-cf63c78aebcf --><!-- end item 96adff53-1a74-480b-866b-4025c67e5461 --></div></section><section aria-labelledby="managing-nocturnal-hypoglycaemia" class="ChapterBody-module--wrapper--2HCfk "><h4 id="managing-nocturnal-hypoglycaemia">Managing nocturnal hypoglycaemia</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c495ce41-01e0-48b0-a5c6-ba521a2938d3 --><!-- begin field bf26102e-cc54-4698-9a06-a1c5b9bce8e3 --><ul><li><strong>If the person is experiencing symptoms of nocturnal hypoglycaemia (fatigue, headache, or a hangover sensation), and/or if this is detected on blood glucose monitoring: </strong><ul><li>Review the person's/family knowledge of blood glucose monitoring and diabetes self-management skills.</li><li>Review the person's current insulin regimen, evening eating habits, and recent/changes in exercise or physical activity.</li><li>Advise the person to:<ul><li>Monitor blood glucose levels overnight, including between 2–3 am, when hypoglycaemia is most likely to happen. </li><li>Eat a snack before bedtime and keep a source of <a class="topic-reference internal-reference" href="index.html#managing-acute-hypoglycaemia">fast-acting carbohydrate</a> next to the bed.</li></ul></li><li>Consider referring the person to the diabetes specialist team for a review of the current insulin regimen.</li></ul></li></ul><!-- end field bf26102e-cc54-4698-9a06-a1c5b9bce8e3 --><!-- end item c495ce41-01e0-48b0-a5c6-ba521a2938d3 --></div></section><section aria-labelledby="preventing-hypoglycaemic-episodes" class="ChapterBody-module--wrapper--2HCfk "><h4 id="preventing-hypoglycaemic-episodes">Preventing hypoglycaemic episodes</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 04aa041c-040e-4634-86f6-b9a2ccce6a58 --><!-- begin field 1a9c4883-2ad5-4cbd-9b48-411ccd7cbb21 --><ul><li><strong>Ensure the person and family/carers have been given information on:</strong><ul><li>How to recognize <a class="topic-reference internal-reference" href="index.html#recognizing-hypoglycaemia">symptoms</a> of hypoglycaemia, and emergency <a class="topic-reference internal-reference" href="index.html#managing-acute-hypoglycaemia">treatment</a> of episodes of hypoglycaemia.</li><li>The importance of regular <a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">self-monitoring</a> of blood glucose levels.</li><li>Keeping safe when driving, reducing the risk of hypoglycaemia, self-monitoring of blood glucose levels, and the medical standards that need to be met to be issued a driving licence by the Driver and Vehicle Licensing Agency (DVLA). See the section on <a class="topic-reference internal-reference" href="index.html#driving">Driving</a> for more information.</li></ul></li><li><strong>If hypoglycaemia becomes troublesome or frequent, assess for contributory factors, such as:</strong><ul><li>Inappropriate <a class="topic-reference internal-reference" href="index.html#insulin-regimens">insulin regimen</a>, including incorrect dose distributions and insulin types — consider referring the person to the diabetes specialist team for a review of their current insulin regimen.</li><li>Meal patterns (such as reduced or missed meals), alcohol intake.</li><li>Exercise/physical activity levels and any recent changes in duration and intensity — hypoglycaemia with exercise may occur at the time of exercise or may be delayed by 7–11 hours.</li><li><a class="topic-reference internal-reference" href="index.html#injection-technique">Injection technique</a> and skills.</li><li><a class="topic-reference internal-reference" href="index.html#injection-site-problems">Injection site problems</a>.</li><li><a class="topic-reference internal-reference" href="index.html#managing-impaired-awareness-of-hypoglycaemia">Impaired awareness of hypoglycaemia</a>; young age or learning disability (may be reduced ability to communicate symptoms).</li><li>Other medical conditions, such as diabetic gastroparesis, coeliac disease, or Addison's disease. See the CKS topics on <a class="topic-reference external-reference" href="../../../diabetes-type-2/index.html">Diabetes - type 2</a>, <a class="topic-reference external-reference" href="../../../../coeliac-disease.html">Coeliac disease</a>, and <a class="topic-reference external-reference" href="../../../addisons-disease/index.html">Addison's disease</a> for more information.</li><li>Changes in insulin sensitivity — an insulin-sensitive person will require smaller amounts of insulin to lower blood glucose levels compared with a person who has low sensitivity.</li><li>Concomitant <a class="topic-reference internal-reference" href="index.html#drug-interactions">drugs</a> that may enhance the blood-glucose-lowering effects of insulin.</li><li>Lack of appropriate knowledge and skills for self-management of diabetes, or anxiety about hypoglycaemia. The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/emotions/hypo-anxiety" data-hyperlink-id="5521730e-fdb8-4a55-9e8c-acbb01122e88">What is hypo anxiety?</a> may be helpful.</li></ul></li><li><strong>If there is recurrent <strong><a class="topic-reference internal-reference" href="index.html#recognizing-hypoglycaemia">severe hypoglycaemia</a></strong> that has not responded to other treatments,</strong> arrange referral or liaise with the specialist diabetes team.</li></ul><!-- end field 1a9c4883-2ad5-4cbd-9b48-411ccd7cbb21 --><!-- end item 04aa041c-040e-4634-86f6-b9a2ccce6a58 --></div></section><section aria-labelledby="basis-for-recommendation-db7" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-db7">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item db78169b-5956-4adc-87ad-ef080014f5c0 --><!-- begin field 076f8821-b94b-4a6b-8c56-d6975f93ec0c --><p>The recommendations on hypoglycaemia are largely based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Type 2 diabetes in adults: management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>], <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>], and the key therapeutic topic <em>Safer insulin prescribing</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>]; the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Assessment and management of hypoglycemia in children and adults with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Abraham 2018</a>], <em>Exercise in children and adolescents with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Adolfsson, 2018</a>], <em>Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">DiMeglio, 2018</a>], and <em>Nutritional management in children and adolescents with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Smart, 2018</a>]; the Royal College of Nursing (RCN) guideline <em>Starting injectable treatment in adults with type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>]; the Driver and Vehicle Licensing Agency (DVLA) publication <em>Assessing fitness to drive - a guide for medical professionals</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">DVLA, 2020</a>]; and expert opinion in a review article on diabetes reviews [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>] and in the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><h5>Recognizing hypoglycaemia</h5><ul><li>The information on the definitions of different severities of hypoglycaemia is based on the NICE key therapeutic topic [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>], the RCN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>], and the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Abraham 2018</a>].</li></ul><h5>Managing hypoglycaemic unawareness</h5><ul><li>The information on the risks of hypoglycaemic unawareness and the importance of education is based on the NICE key therapeutic topic [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>] and the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Abraham 2018</a>]. The definition of impaired awareness of hypoglycaemia for group 1 drivers is based on the DVLA publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">DVLA, 2020</a>].</li></ul><h5>Managing acute hypoglycaemia</h5><ul><li>The recommendations on emergency management of acute hypoglycaemia are based on the NICE key therapeutic topic [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>], the RCN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>], the ISPAD clinical practice consensus guidelines on hypoglycaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">Abraham 2018</a>] and on exercise [<a class="bibliography-reference internal-reference" href="../../references/index.html">Adolfsson, 2018</a>], and expert opinion in the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].<ul><li>The examples of fast-acting carbohydrates are based on the RCN guideline and the BNF.</li><li>The examples of longer-acting carbohydrates are based on the RCN guideline.</li><li>The information on the indications for intramuscular (IM) glucagon and intravenous (IV) glucose is based on the ISPAD guidelines on hypoglycaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">Abraham 2018</a>] and expert opinion in the BNF.</li></ul></li></ul><h5>Managing nocturnal hypoglycaemia</h5><ul><li>The recommendations on nocturnal hypoglycaemia are based on the ISPAD clinical practice consensus guidelines on hypoglycaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">Abraham 2018</a>], on exercise [<a class="bibliography-reference internal-reference" href="../../references/index.html">Adolfsson, 2018</a>], and on nutrition [<a class="bibliography-reference internal-reference" href="../../references/index.html">Smart, 2018</a>].<ul><li>The ISPAD guidelines on exercise note that hypoglycaemia may be anticipated during or shortly after exercise but can also occur up to 24 hours after exercise including at night, due to increased insulin sensitivity. This is more likely if exercise has been prolonged or of moderate- or high-intensity [<a class="bibliography-reference internal-reference" href="../../references/index.html">Adolfsson, 2018</a>].</li><li>The ISPAD guidelines on hypoglycaemia note that sleep is a risk time for severe hypoglycaemia and asymptomatic hypoglycaemia, and overnight blood glucose monitoring may be needed [<a class="bibliography-reference internal-reference" href="../../references/index.html">Abraham 2018</a>].</li><li>The ISPAD guidelines on nutrition note that adequate carbohydrate before bed may be needed for people on insulin therapy to prevent nocturnal hypoglycaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">Smart, 2018</a>].</li></ul></li></ul><h5>Preventing hypoglycaemic episodes</h5><ul><li>The recommendation on education about hypoglycaemic episodes is based on the ISPAD guidelines on hypoglycaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">Abraham 2018</a>]. In addition, expert opinion in a review article states the importance of covering the prevention, signs, symptoms, and management of hypoglycaemia at diabetic reviews; self-monitoring of blood glucose including technique, timing, interpretation and acting on results; as well as the DVLA regulations on driving and hypoglycaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</li><li>The recommendation that recurrent problematic hypoglycaemia may need a review of insulin regimen is extrapolated from the ISPAD guidelines on blood glucose monitoring, which emphasize the need for review of treatment targets, insulin regimen, and doses if there is hypoglycaemic unawareness or a history of severe hypoglycaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">DiMeglio, 2018</a>]. It is also based on expert opinion in a review article, which notes that people with a low HbA1c level and/or recurrent hypoglycaemia may need a dose reduction of insulin. People who are older, frail, with significant weight loss, or receiving palliative care are at risk of overtreatment of hyperglycaemia, which may contribute to episodes of hypoglycaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</li><li>The information on other contributory factors for recurrent episodes of hypoglycaemia is based on the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Abraham 2018</a>].</li></ul><!-- end field 076f8821-b94b-4a6b-8c56-d6975f93ec0c --><!-- end item db78169b-5956-4adc-87ad-ef080014f5c0 --></div></section></section><section aria-labelledby="other-adverse-effects-of-insulin" class="ChapterBody-module--wrapper--2HCfk "><h3 id="other-adverse-effects-of-insulin">What are the other adverse effects of insulin?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c9bef02c-4918-4648-bdc5-bcd918b62c96 --><!-- begin field df68e92f-d36f-4e64-8296-0bdc6c16feec --><p><strong>Other possible adverse effects of insulin therapy include:</strong></p><ul><li><strong>Weight gain (common)</strong><ul><li>Increased body weight can further impair glucose control and increase insulin resistance, requiring a further increase in insulin dosage. See the CKS topics on <a class="topic-reference external-reference" href="../../../diabetes-type-2/index.html">Diabetes - type 2</a> and <a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for more information on weight management.</li></ul></li><li><strong>Refraction disorder (vision)</strong><ul><li>On initiation of insulin treatment, transient altered vision may occur if blood glucose levels change markedly. Advise the person not to change their glasses prescription until blood glucose levels have stabilized.</li></ul></li><li><strong>Oedema</strong><ul><li>This occurs mostly in people with <a class="topic-reference internal-reference" href="index.html#persistent-poor-glucose-control">poor glucose control</a> and progressive weight loss who are treated with relatively high doses of insulin. Oedema should resolve within 3–4 days after reduction of the insulin dose, and treatment with a diuretic is not indicated.</li></ul></li><li><strong>Insulin neuritis</strong><ul><li>Rapid improvement in blood glucose control following initiation of insulin therapy can trigger acute symptomatic neuropathy (usually transient).</li></ul></li></ul><!-- end field df68e92f-d36f-4e64-8296-0bdc6c16feec --><!-- end item c9bef02c-4918-4648-bdc5-bcd918b62c96 --></div><section aria-labelledby="basis-for-recommendation-3d0" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-3d0">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3d0d6604-b629-459b-81fe-9d8f9f6bc3ac --><!-- begin field ad89395a-3ba1-43f0-8ab5-c36329895e95 --><p>The information on possible adverse effects of insulin therapy is based on the Royal College of Nursing (RCN) guideline <em>Starting injectable treatment in adults with type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>] and expert opinion in the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><!-- end field ad89395a-3ba1-43f0-8ab5-c36329895e95 --><!-- end item 3d0d6604-b629-459b-81fe-9d8f9f6bc3ac --></div></section></section><section aria-labelledby="drug-interactions" class="ChapterBody-module--wrapper--2HCfk "><h3 id="drug-interactions">What drug interactions are associated with insulin?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 24481857-585e-4668-958a-f3f4760ea174 --><!-- begin field 7ac40ca0-92e2-4529-a7ba-52ba70d05fca --><ul><li><strong>Drugs that can enhance the blood-glucose-lowering effects of insulin (and hence reduce insulin requirement) include:</strong><ul><li>Alcohol — signs of <a class="topic-reference internal-reference" href="index.html#hypoglycaemia">hypoglycaemia</a> may also become less clear following alcohol intake, and delayed hypoglycaemia may occur (potentially hours after alcohol consumption). The person should:<ul><li>Eat a carbohydrate-containing snack (such as a sandwich) before and after drinking alcohol. Extra insulin is not required. </li><li>Measure their blood glucose regularly and maintain their blood glucose with appropriate carbohydrate intake. </li><li>Always wear some form of <a class="topic-reference internal-reference" href="index.html#accessories-for-insulin-therapy">diabetes identification</a> due to the risk of reduced awareness of hypoglycaemia.</li></ul></li><li>Anabolic steroids.</li><li>Angiotensin-converting enzyme (ACE) inhibitors.</li><li>Beta-blockers — may also mask the warning signs of hypoglycaemia (such as tremor).</li><li>Fibrates.</li><li>Monoamine oxidase inhibitors (MAOIs).</li><li>Salicylates.</li><li>Sulphonamides.</li></ul></li><li><strong>Drugs that can antagonize the blood-glucose-lowering effects of insulin (and hence increase insulin requirement) include:</strong><ul><li>Corticosteroids.</li><li>Danazol.</li><li>Diuretics (loop and thiazides).</li><li>Glucagon.</li><li>Growth hormone.</li><li>Levothyroxine.</li><li>Oral contraceptives.</li><li>Sympathomimetic drugs (such as adrenaline, salbutamol, and terbutaline).</li></ul></li></ul><!-- end field 7ac40ca0-92e2-4529-a7ba-52ba70d05fca --><!-- end item 24481857-585e-4668-958a-f3f4760ea174 --></div><section aria-labelledby="basis-for-recommendation-fd4" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-fd4">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item fd4a0c69-912b-4832-80b4-363d1d8e44e5 --><!-- begin field 6b34f05e-d066-4ec3-9cda-750335986aed --><p>The information on drug interactions is based on the Royal College of Nursing (RCN) guideline <em>Starting injectable treatment in adults with type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>], expert opinion in the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>], and a pharmaceutical reference book [<a class="bibliography-reference internal-reference" href="../../references/index.html">Preston, 2020</a>].</p><!-- end field 6b34f05e-d066-4ec3-9cda-750335986aed --><!-- end item fd4a0c69-912b-4832-80b4-363d1d8e44e5 --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/insulin-therapy-in-type-2-diabetes/management/insulin-therapy-type-2-diabetes/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>